Ocugen (OCGN) Non-Current Deffered Revenue (2014 - 2019)
Ocugen (OCGN) reported Non-Current Deffered Revenue of $10.0 million for Q2 2019, up 3054.57% on a YoY basis from $317000.0 in Q2 2018, and little changed quarter-over-quarter from $10.0 million in Q1 2019.
Ocugen (OCGN) Non-Current Deffered Revenue (2014 - 2019) Analysis & Trends
Ocugen has reported Non-Current Deffered Revenue for 6 years, with the latest figure at $10.0 million in Q2 2019.
- For the quarter ending Q2 2019, Non-Current Deffered Revenue rose 3054.57% year-over-year to $10.0 million; the trailing twelve-month figure through Jun 2019 stood at $10.0 million (up 3054.57% YoY), and the FY2018 full-year result was $3739.0, down 98.66% from the prior year.
- Non-Current Deffered Revenue for Q2 2019 stood at $10.0 million, roughly flat from $10.0 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $10.0 million in Q1 2019, with the low at $3739.0 in Q4 2018.
- Historically, Non-Current Deffered Revenue has averaged $1.7 million across 5 years, with a median of $365000.0 in 2015.
- Annual changes were most pronounced in 2018 — Non-Current Deffered Revenue slumped 98.66% — and 2019, when it surged 3244.48%.
- Ocugen's Non-Current Deffered Revenue stood at $451000.0 in 2015, then plunged by 30.16% to $315000.0 in 2016, then retreated by 11.11% to $280000.0 in 2017, then tumbled by 98.66% to $3739.0 in 2018, then surged by 267351.19% to $10.0 million in 2019.
- The last three Non-Current Deffered Revenue figures came in at $10.0 million (Q2 2019), $10.0 million (Q1 2019), and $3739.0 (Q4 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ocugen | 411.07 Mn | 411.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 10.00 Mn |
| Mar 31, 2019 | 10.00 Mn |
| Dec 31, 2018 | 3,739.00 |
| Sep 30, 2018 | 5.00 Mn |
| Jun 30, 2018 | 317,000.00 |
| Mar 31, 2018 | 299,000.00 |
| Dec 31, 2017 | 280,000.00 |
| Sep 30, 2017 | 289,000.00 |
| Jun 30, 2017 | 298,000.00 |
| Mar 31, 2017 | 308,000.00 |
| Dec 31, 2016 | 315,000.00 |
| Sep 30, 2016 | 349,000.00 |
| Jun 30, 2016 | 384,000.00 |
| Mar 31, 2016 | 418,000.00 |
| Dec 31, 2015 | 451,000.00 |
| Sep 30, 2015 | 381,000.00 |
| Jun 30, 2015 | 413,000.00 |
| Mar 31, 2015 | 445,000.00 |
| Dec 31, 2014 | 379,000.00 |